IVI’s research brief series, Value Blueprints, profiles learnings from the Open-Source Value Project to spark exploration among health economics and outcomes research community into advancing next-generation value assessment methods.
May 31, 2021
In making treatment decisions, what’s important to patients living with major depressive disorder? This new research brief describes the application of a patient-driven value elements framework in identifying value elements important to these patients. IVI is partnering with the Patient-Driven Values in Healthcare Evaluation (PAVE) at the University of Maryland for this important work.
November 23, 2020
How does open-source modeling contribute to value assessment, and what challenges exist to its expanded use in the field? IVI’s new research brief explores the benefits of open-source modeling in value assessment and discusses the barriers that researchers need to address as interest in this type of modeling and its principles of collaboration, transparency, and rigor grow.
November 10, 2020
How should value assessment evolve to account for diagnostics, therapies, and vaccines to combat the COVID pandemic? IVI’s latest research brief in the Value Blueprints series offers recommendations for improving health economic modeling and better considering the diverse needs of patients and those who pay for care.
December 9, 2019
ICER’s recent assessment of JAK inhibitors for RA raises the question: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? This issue brief discusses the limitations of conventional value assessment approaches in chronic diseases with sequential treatment options and points to new methods being developed by IVI.
Structural assumptions may impact model results, but this structural uncertainty is not generally measured or addressed in cost-effectiveness studies. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. We then show why cost-effectiveness studies should explicitly incorporate and report effects of structural uncertainty to ensure that real-world decision-makers have complete information.
New medical technologies can benefit not only patients, but also healthy people at risk of future illness. The “insurance value” of this decrease in physical risks of illness is an important element in understanding value at the broader population level, but methods for estimating and incorporating are nascent. This brief uses the IVI-RA model to illustrate the application of insurance value and explore potential implications.
May 20, 2019
To ensure that the patient perspective guided the development of IVI’s open-source model for EGFR+ non-small cell lung cancer (NSCLC), IVI partnered with patients to conduct qualitative research on patient experiences with treatment. This brief summarizes the results of these interviews and focus groups with NSCLC patients and insights into what factors determine value from patients’ perspectives.
May 20, 2019
To ensure that the patient perspective guided the development of IVI’s open-source model for EGFR+ non-small cell lung cancer (NSCLC), IVI partnered with patients to conduct qualitative research on patient experiences with treatment. This brief summarizes the results of these interviews and focus groups with NSCLC patients and insights into what factors determine value from patients’ perspectives.